Molecular Templates (MTEM) Competitors $0.46 +0.01 (+2.23%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MTEM vs. COGT, WVE, BMY, SNY, AMGN, VRTX, GILD, REGN, ALNY, and BIIBShould you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Cogent Biosciences (COGT), Wave Life Sciences (WVE), Bristol-Myers Squibb (BMY), Sanofi (SNY), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "medical" sector. Molecular Templates vs. Cogent Biosciences Wave Life Sciences Bristol-Myers Squibb Sanofi Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Cogent Biosciences (NASDAQ:COGT) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Is COGT or MTEM more profitable? Cogent Biosciences has a net margin of 0.00% compared to Molecular Templates' net margin of -61.35%. Cogent Biosciences' return on equity of -100.92% beat Molecular Templates' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -100.92% -57.67% Molecular Templates -61.35%-260.50%-46.90% Which has more risk & volatility, COGT or MTEM? Cogent Biosciences has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Do analysts rate COGT or MTEM? Cogent Biosciences currently has a consensus target price of $14.67, suggesting a potential upside of 25.14%. Given Cogent Biosciences' higher possible upside, equities analysts plainly believe Cogent Biosciences is more favorable than Molecular Templates.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Molecular Templates 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community believe in COGT or MTEM? Molecular Templates received 60 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.68% of users gave Cogent Biosciences an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes28270.68% Underperform Votes11729.32% Molecular TemplatesOutperform Votes34267.32% Underperform Votes16632.68% Do insiders and institutionals hold more shares of COGT or MTEM? 95.5% of Molecular Templates shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by insiders. Comparatively, 13.6% of Molecular Templates shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, COGT or MTEM? Molecular Templates has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$2.48-4.73Molecular Templates$57.31M0.05-$8.12M-$2.70-0.17 Does the media favor COGT or MTEM? In the previous week, Cogent Biosciences had 2 more articles in the media than Molecular Templates. MarketBeat recorded 2 mentions for Cogent Biosciences and 0 mentions for Molecular Templates. Cogent Biosciences' average media sentiment score of 0.83 beat Molecular Templates' score of 0.44 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cogent Biosciences Positive Molecular Templates Neutral SummaryCogent Biosciences beats Molecular Templates on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Molecular Templates News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEM vs. The Competition Export to ExcelMetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.01M$7.02B$5.32B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-0.1710.75121.3415.54Price / Sales0.05396.531,497.9292.41Price / CashN/A47.4339.6734.18Price / Book0.595.604.755.07Net Income-$8.12M$153.56M$118.54M$225.38M7 Day Performance-23.70%-1.46%-0.39%0.07%1 Month Performance-66.46%15.32%6.05%3.93%1 Year Performance-90.84%43.07%38.13%32.51% Molecular Templates Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEMMolecular Templates1.6746 of 5 stars$0.46+2.2%N/A-90.8%$2.96M$57.31M-0.1762Negative NewsCOGTCogent Biosciences2.5863 of 5 stars$12.12+1.9%$14.67+21.0%+43.1%$1.16BN/A-4.8980Upcoming EarningsWVEWave Life Sciences4.9435 of 5 stars$15.02+0.2%$19.44+29.5%+160.9%$1.84B$110.50M-26.35240Analyst ForecastBMYBristol-Myers Squibb4.521 of 5 stars$52.47-0.3%$53.57+2.1%+6.0%$106.36B$46.51B-16.1034,100Earnings ReportAnalyst ForecastShort Interest ↑News CoverageSNYSanofi2.5586 of 5 stars$54.01-0.6%$57.50+6.5%+15.0%$137.07B$46.61B27.5686,088Earnings ReportAnalyst UpgradeAnalyst RevisionAMGNAmgen4.5954 of 5 stars$315.52-0.5%$332.55+5.4%+22.4%$169.26B$30.93B54.3126,700Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionVRTXVertex Pharmaceuticals3.4636 of 5 stars$475.32-0.2%$492.92+3.7%+27.6%$122.68B$9.87B-234.155,400Upcoming EarningsAnalyst ForecastGILDGilead Sciences4.9367 of 5 stars$87.97-0.9%$86.85-1.3%+11.6%$109.60B$27.81B107.2818,000Upcoming EarningsAnalyst ForecastREGNRegeneron Pharmaceuticals4.8471 of 5 stars$926.62-0.2%$1,101.00+18.8%+6.6%$102.15B$13.12B24.5413,450Analyst ForecastAnalyst RevisionNews CoverageALNYAlnylam Pharmaceuticals3.9488 of 5 stars$284.75-0.8%$290.86+2.1%+74.5%$36.02B$2.34B-474.582,100Analyst ForecastShort Interest ↑News CoverageBIIBBiogen4.8416 of 5 stars$184.66-0.2%$271.39+47.0%-27.5%$26.89B$9.67B23.267,570Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies COGT Competitors WVE Competitors BMY Competitors SNY Competitors AMGN Competitors VRTX Competitors GILD Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MTEM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
